Guidance and Visibility Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Guidance and Visibility

AAPL 271.50

+2.0%

Nov 21 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: SusieQ1065 who wrote (15045)	9/9/2001 9:42:51 AM
From: 2MAR$	Read Replies (1) of 208838

Scientists, companies clash over research (Embargoed for release 6:30 p.m. EDT/2230 GMT) WASHINGTON, Sept 9 (Reuters) - The editors of the world's most prestigious medical journals unveiled a new policy on Sunday aimed at limiting the influence of pharmaceutical companies in research they fund involving their own products. Following are examples of some recent controversies. -- In 2000, scientists at the University of California at San Francisco (UCSF) acted against the wishes of Immune Response Corp. <IMNR.O>, which had sponsored their research, and published a study that found that one of the firm's HIV therapies did not help patients already getting standard treatment. The company then sued the university for allegedly hurting its business. -- Knoll Pharmaceutical Co. for seven years prevented the publication of a study it had funded conducted by UCSF clinical pharmacist Betty Dong that did not come to the conclusion it had wanted. The study found that the company's thyroid medication Synthroid was no more or less effective than less costly competitors. The company in 1999 agreed to pay 37 states more than $40 million to settle a lawsuit charging that it had impeded the publication of the study and made false claims about the superiority of its product. -- University of Toronto liver specialist Nancy Olivieri lost her research contract with Canadian firm Apotex Inc. after she defied the company and published in 1998 an article on research it had funded that called into question the safety and effectiveness of one of the company's drugs. The drug was for treating the blood disease thalassemia. The company maintains it dumped her contract because she did not follow the protocol it had devised for conducting the study not because of the results. ((Will Dunham, Washington newsroom, +1 202 898 8300, fax +1 202 898 8383, washington.bureau.newsroom@reuters.com)) REUTERS * end of story *

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next